Microarray In Node negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy - A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. (EORTC Protocol 10041 – BIG 3-04).

Trial Profile

Microarray In Node negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy - A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. (EORTC Protocol 10041 – BIG 3-04).

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary) ; Anthracyclines
  • Indications Early breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms MINDACT
  • Most Recent Events

    • 13 Jun 2017 Results published in an Agendia media release.
    • 02 Jun 2017 Results (n=1301) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jan 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top